Pharma Equity Group A/S (PEG.CO)
DKK 0.08
(-2.32%)
DKK 0.08
(-2.32%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 30.22 Million DKK | 32.31% |
| 2022 | 22.84 Million DKK | 20.69% |
| 2021 | 18.92 Million DKK | 88.48% |
| 2020 | 10.04 Million DKK | 504.15% |
| 2019 | 1.66 Million DKK | 11.84% |
| 2018 | 1.48 Million DKK | 1342.72% |
| 2017 | 103 Thousand DKK | -98.56% |
| 2016 | 7.14 Million DKK | -69.2% |
| 2015 | 23.2 Million DKK | 154626.67% |
| 2014 | 15 Thousand DKK | -100.0% |
| 2013 | 322.39 Million DKK | 34.48% |
| 2012 | 239.72 Million DKK | 27.75% |
| 2011 | 187.66 Million DKK | -22.19% |
| 2010 | 241.19 Million DKK | 2298.49% |
| 2009 | 10.05 Million DKK | -95.08% |
| 2008 | 204.58 Million DKK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 43.87 Million DKK | 11.92% |
| 2024 Q1 | 39.2 Million DKK | 29.72% |
| 2023 Q2 | 21.5 Million DKK | 1.13% |
| 2023 Q1 | 21.26 Million DKK | -6.88% |
| 2023 Q3 | 22.66 Million DKK | 5.38% |
| 2023 FY | 30.22 Million DKK | 32.31% |
| 2023 Q4 | 30.22 Million DKK | 33.33% |
| 2022 Q2 | 20.64 Million DKK | 0.0% |
| 2022 FY | 22.84 Million DKK | 20.69% |
| 2022 Q4 | 22.84 Million DKK | 0.0% |
| 2021 FY | 18.92 Million DKK | 88.48% |
| 2021 Q4 | 18.92 Million DKK | 0.0% |
| 2021 Q2 | 8.33 Million DKK | 0.0% |
| 2020 Q4 | 10.04 Million DKK | 0.0% |
| 2020 FY | 10.04 Million DKK | 504.15% |
| 2020 Q2 | 3.63 Million DKK | 0.0% |
| 2019 Q4 | 1.66 Million DKK | 0.0% |
| 2019 Q2 | 1 Million DKK | 0.0% |
| 2019 FY | 1.66 Million DKK | 11.84% |
| 2018 Q4 | 1.48 Million DKK | 0.0% |
| 2018 FY | 1.48 Million DKK | 1342.72% |
| 2018 Q2 | 1.4 Million DKK | 0.0% |
| 2017 Q2 | 5.5 Million DKK | 0.0% |
| 2017 FY | 103 Thousand DKK | -98.56% |
| 2017 Q4 | 103 Thousand DKK | 0.0% |
| 2016 Q2 | 5.1 Million DKK | 0.79% |
| 2016 FY | 7.14 Million DKK | -69.2% |
| 2016 Q1 | 5.06 Million DKK | -78.18% |
| 2015 Q2 | 1.43 Million DKK | 31.74% |
| 2015 Q4 | 23.2 Million DKK | 244.04% |
| 2015 Q1 | 1.09 Million DKK | 7166.67% |
| 2015 FY | 23.2 Million DKK | 154626.67% |
| 2015 Q3 | 6.74 Million DKK | 369.78% |
| 2014 Q4 | 15 Thousand DKK | -99.98% |
| 2014 Q3 | 72.39 Million DKK | 0.37% |
| 2014 FY | 15 Thousand DKK | -100.0% |
| 2014 Q1 | 21.36 Million DKK | -93.37% |
| 2014 Q2 | 72.12 Million DKK | 237.62% |
| 2013 Q2 | 191.46 Million DKK | -18.31% |
| 2013 FY | 322.39 Million DKK | 34.48% |
| 2013 Q3 | 191.72 Million DKK | 0.13% |
| 2013 Q4 | 322.39 Million DKK | 68.15% |
| 2013 Q1 | 234.39 Million DKK | -2.23% |
| 2012 Q3 | 233.43 Million DKK | -37.34% |
| 2012 FY | 239.72 Million DKK | 27.75% |
| 2012 Q4 | 239.72 Million DKK | 2.7% |
| 2012 Q1 | 387.24 Million DKK | 106.35% |
| 2012 Q2 | 372.51 Million DKK | -3.8% |
| 2011 Q2 | 349.56 Million DKK | -0.08% |
| 2011 FY | 187.66 Million DKK | -22.19% |
| 2011 Q3 | 225.25 Million DKK | -35.56% |
| 2011 Q4 | 187.66 Million DKK | -16.69% |
| 2011 Q1 | 349.83 Million DKK | 45.04% |
| 2010 FY | 241.19 Million DKK | 2298.49% |
| 2010 Q2 | 29.7 Million DKK | 0.0% |
| 2010 Q3 | 29.81 Million DKK | 0.35% |
| 2010 Q4 | 241.19 Million DKK | 709.04% |
| 2009 FY | 10.05 Million DKK | -95.08% |
| 2009 Q4 | 10.05 Million DKK | 0.0% |
| 2008 FY | 204.58 Million DKK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ALK-Abelló A/S | 765 Million DKK | 96.05% |
| Bavarian Nordic A/S | 145.3 Million DKK | 79.201% |
| Genmab A/S | 770 Million DKK | 96.075% |
| Gubra A/S | 71.43 Million DKK | 57.694% |
| Novo Nordisk A/S | 27 Billion DKK | 99.888% |
| Orphazyme A/S | - DKK | -Infinity% |
| Zealand Pharma A/S | 200.27 Million DKK | 84.91% |